AllianceBernstein’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20.2M Buy
398,005
+4,030
+1% +$209K 0.01% 912
2026
Q1
$11.6M Sell
393,975
-11,231
-3% -$524K ﹤0.01% 1134
2025
Q4
$11.9M Sell
405,206
-9,452
-2% -$257K ﹤0.01% 1161
2025
Q3
$10.7M Sell
414,658
-13,006
-3% -$363K ﹤0.01% 1182
2025
Q2
$11.8M Buy
427,664
+73,896
+21% +$1.95M ﹤0.01% 1105
2025
Q1
$10M Buy
353,768
+22,329
+7% +$792K ﹤0.01% 1158
2024
Q4
$13.8M Buy
331,439
+1,705
+0.5% +$81.5K ﹤0.01% 1037
2024
Q3
$22M Sell
329,734
-75,971
-19% -$6.98M 0.01% 874
2024
Q2
$48.2M Buy
405,705
+20,343
+5% +$2.57M 0.02% 603
2024
Q1
$41.1M Sell
385,362
-31,264
-8% -$3.15M 0.01% 659
2023
Q4
$41.4M Sell
416,626
-28,598
-6% -$2.41M 0.02% 643
2023
Q3
$46M Buy
445,224
+47,962
+12% +$5.35M 0.02% 584
2023
Q2
$48.3M Sell
397,262
-1,580
-0.4% -$211K 0.02% 583
2023
Q1
$61.3M Sell
398,842
-91,916
-19% -$15.2M 0.03% 508
2022
Q4
$88.1M Sell
490,758
-13,984
-3% -$2.29M 0.04% 413
2022
Q3
$59.7M Sell
504,742
-5,657
-1% -$858K 0.03% 494
2022
Q2
$72.9M Buy
510,399
+38,595
+8% +$5.52M 0.03% 453
2022
Q1
$81.3M Sell
471,804
-35,100
-7% -$5.91M 0.03% 460
2021
Q4
$129M Sell
506,904
-25,884
-5% -$7.57M 0.05% 369
2021
Q3
$205M Buy
532,788
+350,317
+192% +$129M 0.08% 224
2021
Q2
$42.9M Buy
182,471
+15,755
+9% +$2.82M 0.02% 662
2021
Q1
$21.8M Buy
166,716
+6,463
+4% +$937K 0.01% 899
2020
Q4
$16.7M Sell
160,253
-39
-0% -$3.95K 0.01% 923
2020
Q3
$11.3M Buy
160,292
+11,270
+8% +$786K 0.01% 988
2020
Q2
$9.57M Buy
149,022
+30,701
+26% +$1.68M 0.01% 1021
2020
Q1
$3.54M Buy
118,321
+20,860
+21% +$480K ﹤0.01% 1344
2019
Q4
$1.91M Buy
97,461
+37,040
+61% +$657K ﹤0.01% 1995
2019
Q3
$962K Buy
60,421
+6,664
+12% +$98.4K ﹤0.01% 2268
2019
Q2
$787K Buy
53,757
+35,030
+187% +$752K ﹤0.01% 2414
2019
Q1
$381K Buy
+18,727
New +$348K ﹤0.01% 2644

Other funds holding MRNA

AllianceBernstein's MRNA Position: Q2 2026 in Review

AllianceBernstein increased its Moderna (MRNA) stake by 1% in Q2 2026, buying an estimated $209K and bringing the position to 398,005 shares worth $20.2M. The position accounts for 0.01% of the portfolio, ranked #912.

AllianceBernstein first reported a position in MRNA in Q1 2019 and has held it in 30 quarters since. The position peaked at $205M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • AllianceBernstein held 398,005 shares of Moderna worth $20.2M as of Q2 2026.
  • AllianceBernstein bought 4,030 Moderna shares in Q2 2026, an estimated $209K.
  • Moderna made up 0.01% of AllianceBernstein's portfolio in Q2 2026, its #912 holding.
  • AllianceBernstein first reported a position in Moderna in Q1 2019 and has held it in 30 quarters since.
  • AllianceBernstein's Moderna position peaked at $205M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.